Qualiclinic Kft.
- Address
- lock Available on a paid plan
Immune System Diseases
Qualiclinic Kft. is advancing research in immune system diseases, concentrating on autoimmune disorders where novel biologic agents are being tested for safety and effectiveness.
- Active Psoriatic Arthritis
- Moderate to Severe Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Sjögren’s Disease
- Cutaneous Lupus Erythematosus
The trials compare new targeted therapies with existing standards of care, aiming to improve disease control, reduce flare frequency, and enhance quality of life for patients with these conditions.
Musculoskeletal Diseases
Studies at the Budapest clinic focus on musculoskeletal diseases, evaluating treatments that can alleviate joint pain and slow disease progression.
- Knee Osteoarthritis
- Moderate to Severe Rheumatoid Arthritis
- Active Psoriatic Arthritis
- Psoriatic Arthritis (PsA)
Researchers are measuring improvements in pain scores, functional mobility, and inflammatory markers to determine whether new medications can provide better long‑term outcomes for patients with joint disorders.
Nutritional and Metabolic Diseases
The site’s program in nutritional and metabolic diseases addresses the growing need for effective weight‑management and glucose‑control strategies.
- Overweight and obesity
- Type 2 Diabetes
- Type 2 Diabetes Mellitus (T2D)
Clinical investigations test innovative peptide and small‑molecule agents to achieve meaningful weight loss and lower HbA1c levels, offering additional tools for patients struggling with obesity‑related diabetes.
Skin and Connective Tissue Diseases
Research efforts target skin and connective tissue diseases, particularly conditions that cause chronic skin inflammation and systemic involvement.
- Moderate-to-Severe Plaque Psoriasis
- Cutaneous Lupus Erythematosus
- Active Psoriatic Arthritis
Trials evaluate whether emerging biologics can clear skin lesions, reduce disease activity scores, and improve patients’ daily comfort and self‑esteem.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 41 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 41 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Janssen Cilag International3active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International6trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Qualiclinic Kft.
lock Showing 1 of 33 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 41 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Emtricitabine | 3 | Unknown | 2023-02-03 | 2024-11-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.